In conclusion, we were able to confirm the functional HSF1-CPT1a signaling pathway at different stages of NAFLD and describe this pathway as a potential pharmacological target for the clinical management of metabolic fatty liver diseases. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.